Inclusion Criteria:

- Japanese or Korean with voluntary written informed consent for study participation

- A histologically or cytologically confirmed advanced/recurrent gastric cancer

- One or two prior chemotherapy regimens for advanced/recurrent gastric cancer

- At least one measurable lesion

- ECOG performance status of 0 or 1

- Life expectancy ≥3 months

Exclusion Criteria:

- Surgery for cancer within 4 weeks prior to the first dose of ARQ 197

- Confirmed other tumors than gastric cancer within 5 years prior to the first dose of
ARQ 197

- Anticancer chemotherapy, hormone therapy, radiotherapy or immunotherapy within 2
weeks prior to the first dose of ARQ 197

- Positive for HIV antibody

- Known symptomatic brain metastasis

- Gastrointestinal disorders that could interfere with the absorption of ARQ 197 or
operation history for gastrointestinal disorders

- Uncontrolled concomitant disease

- Patients who wish to have a child and who would not agree to use contraceptive
measures

- Pregnant or lactating